Bio-Me news
The Microbiome Therapeutics Innovation Group (MTIG) today announced the addition of Bio-Me to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products.
Bio-Me offers a wide range of proprietary solutions to facilitate the gut microbiome analysis process for academia and pharma researchers and is setting the standard for next-generation routine microbiome analysis with its Precision Microbiome Profiling (
Microbiome precision medicine company Bio-Me today announced that Dr. Warren Flood has become CEO following his successful period as COO. Previous CEO Dr. Morten Isaksen moves up to the Board and will also continue as Chief Innovation Officer with a focus on longer term and higher-value clinical applications for the company’s Precision Microbiome Profiling (PMP™) technology. These steps are part of the company’s strategic plan to position Bio-Me as a leader in microbiome-bas
On September 22nd Warren Flood, Ph.D. and COO of Bio-Me, will participate in a webinar organized together with Thermo Fisher Scientific with the title “Missing a piece of the puzzle? Factor in the gut microbiome”. There, he will present how our PMP platform, based on Thermo Fisher Scientific’s OpenArray qPCR technology, helps researchers and industry translating their gut microbiome discoveries into future solutions and applications.
On July 1st Bio-Me has two back-to-back presentations. Our Founder and CEO, Morten L. Isaksen will first be presenting how we support companies in their development of microbiome modulating drugs with our PMP™ technology for targeted microbiome analysis. Following that, our COO Warren Flood will do a joint presentation with Ricardo Valladares, CSO at Siolta Therapeutics showcasing how we work together to facilitate their drug development in infant allergic
Bio-Me today announced a major board restructuring with Carl Christian Glilhuus-Moe stepping up to the Executive Chair position. He is joined by new board members Hilde Furberg, Anne-Marie Duus Kristensen, and Arne Materna who collectively bring a wealth of diagnostic, microbiology, and commercialization experience as the Company enters a new phase of development following a recent succes
Microbiome Dx company Bio-Me and Siolta Therapeutics today announced that they have entered into a collaboration and marketing agreement. Under the agreement, Siolta will provide both samples and insights into key criteria for Bio-Me to develop a rapid, detailed and comprehensive diagnostic test for infants at risk of developing allergy and asthma.
The test will be offered to parents of new-borns in order to help them take preventive steps to minimize the
Bio-Me, a pioneer in rapid gut microbiome analysis is announcing the opening of its gut microbiome analysis service laboratory. This will enable the Research & Development departments worldwide to access their Precision Microbiome Profiling (PMP™) platform.
The service laboratory is located at the Oslo’s Science Park’s premier lab sharing facility, the ShareLab. The lab opening will feature comments from Peter Jacobs, associate director at Genetic Analysis, Cl
During the 4th Norwegian National Microbiota Conference to be held in Oslo, Norway on 9th November, Dr. Morten Isaksen, CEO of Bio-Me has been invited to present Bio-Me and its contribution to use of information from the gut microbiome in clinical settings.
The Conference gathers different groups that work within the field of microbiome/microbiota related aspects in Norway. This field is rapidly growing and gaining momentum in Norway, and this is the first time th